Loading...
•
Oct 03, 2025
Aramark Q4 2025 Earnings Report
Aramark reported steady results with revenue growth and improved adjusted EPS in Q4 2025.
Key Takeaways
Aramark delivered strong revenue growth in Q4 2025, fueled by new business and high client retention. Adjusted EPS rose, although GAAP EPS declined due to a non-cash impairment. Operating income remained flat compared to the previous year.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Aramark expects continued strong growth in FY26, targeting 7–9% organic revenue growth and 20–25% adjusted EPS growth, with plans to reduce leverage below 3x.
Positive Outlook
- Revenue expected to reach $19.55–$19.95 billion
- Adjusted EPS guided between $2.18–$2.28
- Adjusted Operating Income expected to grow 12–17%
- Leverage ratio targeted under 3x
- Strong pipeline of new client wins already in place for FY26
Challenges Ahead
- GAAP EPS in Q4 impacted by non-cash impairment
- Some onboarding costs and incentive compensation weighed on Q4 margins
- Higher corporate expenses due to incentive payouts
- Challenges in medical prescription costs impacted results
- Timing of new business launches affected short-term income
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...